Blog: Ask a Student Pharmacist

JUNE 21, 2023

Particularly, we devote a large portion of our research to identifying novel compounds that impact cellular uptake or inhibit drug efflux - the most common mechanism underlying acquired drug resistance in cancer, pinpointing the transporters or targets involved in these processes, and evaluating regimens to produce desirable anti-cancer responses.

Compounding 40

Compounding Chemotherapy Immunization 40

European Pharmaceutical Review

SEPTEMBER 12, 2023

A T-cell epitope cancer vaccine significantly improved overall survival in non-small cell lung cancer (NSCLC) compared to chemotherapy, Phase III data published in Annals of Oncology has shown. percent with chemotherapy. months for chemotherapy. The overall survival rate at one year with Tedopi was 44.4 percent versus 27.5

Vaccines 98

Vaccines Chemotherapy Immunization 98

European Pharmaceutical Review

JUNE 27, 2023

difficile infection by the end of 2024 and will be announcing first patient dosed in the Phase II clinical trial of VE202 for ulcerative colitis (UC) shortly too. How do you envision microbiome therapies complementing existing cancer treatments, such as chemotherapy and immunotherapy?

Chemotherapy 105

Chemotherapy Immunization FDA Vaccines 105

pharmaphorum

SEPTEMBER 6, 2022

The Nijmegen, Netherlands-based biotech was founded in 2018 to develop therapies designed to change the balance of protein expression within the tumour ‘microenvironment’, which can defend cancers against the immune system, and is increasingly becoming a source of new targets in oncology. The Series A round includes €3.6

Chemotherapy 103

Chemotherapy Immunization FDA 103

European Pharmaceutical Review

APRIL 10, 2024

While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Notably, from one donor to another, significant variations exist.

Immunization 95

Immunization Chemotherapy FDA Pharmaceutical Companies 95

pharmaphorum

OCTOBER 4, 2020

However it requires high-dose chemotherapy to destroy the bone marrow, and that poses significant risks to patients in its own right, and can also lead to graft-versus-host disease, a potentially life-threatening complication in which the bone marrow donor’s immune cells attack the recipient’s cells and tissues.

Immunization 98

Immunization Chemotherapy FDA 98

European Pharmaceutical Review

SEPTEMBER 25, 2023

The humanised IgG4 anti-PD-1 antibody is indicated for unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (ESCC) after prior platinum-based chemotherapy. The FDA’s target action date is the second half of 2024. months for chemotherapy. months for TEVIMBRA versus 6.3

Chemotherapy 105

Chemotherapy FDA Immunization 105

PharmaShots

MARCH 29, 2023

It is the only drug in its class of chemotherapy and is developed from the natural substance found in a sea sponge. According to the Novo Nordisk legal settlement with its competitors, though the Victoza patent expires in 2023, the drug wouldn’t face generic competition until 2024.

FDA 49

FDA Chemotherapy Immunization Dosage 49

PQA

NOVEMBER 1, 2024

We are excited to host members next week at the 2024 PQA Leadership Summit and PQA Convenes: Quality Medication Use in Rare Disease at the Renaissance Arlington Capital View Hotel in Arlington, Va. Thank you to our 2024 PQA Leadership Summit sponsors! There is still time for members to join us at both events!

Specialty Pharmacies 52

Specialty Pharmacies Vaccines Chemotherapy Immunization 52

Hospital Pharmacy Europe

FEBRUARY 15, 2024

They are] administered by the same nurses who would normally give chemotherapy’, Dr Tucker says. Other potential barriers lie in the risks associated with stimulation of the immune system, which we also need for these agents to work’, Dr Walter continues.

Chemotherapy 52

Chemotherapy Hospitals Immunization Vaccines 52

European Pharmaceutical Review

FEBRUARY 3, 2025

Biosimilars given a positive opinion Dyrupeg (pegfilgrastim) to reduce the duration of neutropenia and help prevent febrile neutropenia following chemotherapy. The EC questioned whether this would necessitate an update of the CHMPs opinion made in November 2024.

Generic Medicine 52

Generic Medicine Vaccines Chemotherapy Immunization 52